JCM
HUMA icon

Jacobi Capital Management’s Humacyte HUMA Stock Holding History

Jacobi Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-560
Closed -$7K – 801
2021
Q3 		$7K Buy
+560
New +$6.41K ﹤0.01% 1124

Other funds holding HUMA

YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jacobi Capital Management's HUMA Position: Q4 2021 in Review

Jacobi Capital Management sold out of Humacyte (HUMA) in Q4 2021, closing a stake of 560 shares — an estimated $7K sold.

Jacobi Capital Management first reported a position in HUMA in Q3 2021 and held it in 1 quarter. The position peaked at $7K in Q3 2021. 61 funds tracked by Wall St. Rank hold HUMA as of Q4 2021.

  • Jacobi Capital Management reported no remaining Humacyte position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 560 Humacyte shares in Q4 2021, an estimated $7K.
  • Jacobi Capital Management first reported a position in Humacyte in Q3 2021 and held it in 1 quarter.
  • Jacobi Capital Management's Humacyte position peaked at $7K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Humacyte as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.